Clinical Characteristics Associated with Poor Prognosis of Acquired Immunodeficiency Syndrome Patients Complicated with Disseminated Talaromycosis marneffei

References

• Le T, Kinh NV, Cuc NTK, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis. N Engl J Med. 2017;376(24):2329–2340. doi:10.3760/cma.j.issn.0253-2727.2019.01.010
   PubMed Web of Science ®Google Scholar
• Li Y, Chen H, Li S, et al. LncSSBP1 functions as a negative regulator of IL-6 through interaction with hnRNPK in bronchial epithelial cells infected with talaromyces marneffei. Front Immunol. 2019;10:2977. doi:10.3389/fimmu.2019.02977
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang R, Shen Y, et al. Clinical characteristics and prognosis of penicilliosis among human immunodeficiency virus-infected patients in eastern China. Am J Trop Med Hyg. 2017;96(6):1350–1354. doi:10.4269/ajtmh.16-0521
   PubMed Web of Science ®Google Scholar
• Dong RJ, Zhang YG, Zhu L, et al. Innate immunity acts as the major regulator in Talaromyces marneffei coinfected AIDS patients: cytokine profile surveillance during initial 6-month antifungal therapy. Open Forum Infect Dis. 2019;6(6):ofz205. doi:10.1093/ofid/ofz205
   PubMed Web of Science ®Google Scholar
• Peng L, Shi YB, Zheng L, et al. Clinical features of patients with talaromycosis marneffei and microbiological characteristics of the causative strains. J Clin Lab Anal. 2022;36(11):e24737. doi:10.1002/jcla.24737
   PubMed Web of Science ®Google Scholar
• AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition). Zhonghua Nei Ke Za Zhi. 2021;60(12):1106–1128. doi:10.3760/cma.j.cn112138-20211006-00676
   PubMedGoogle Scholar
• Huang W, Li T, Zhou C, et al. Voriconazole versus amphotericin B as induction therapy for Talaromycosis in HIV/AIDS patients: a retrospective study. Mycopathologia. 2021;186(2):269–276. doi:10.1007/s11046-021-00533-5
   PubMed Web of Science ®Google Scholar
• Panapruksachat S, Iwatani S, Oura T, et al. Identification and functional characterization of Penicillium marneffei pleiotropic drug resistance transporters ABC1 and ABC2. Med Mycol. 2016;54(5):478–491. doi:10.1093/mmy/myv117
   PubMed Web of Science ®Google Scholar
• Lai J, Liu Y, Ye H, et al. Talaromyces marneffei is the persistent overwhelming bloodstream infection pathogen among HIV inpatients in Fujian, China. Infect Drug Resist. 2022;15:5207–5214. doi:10.2147/IDR.S379100
   PubMed Web of Science ®Google Scholar
• Le T, Wolbers M, Chi NH, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City. Viet Nam Clin Infect Dis. 2011;52(7):945–952. doi:10.1093/cid/cir028
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang J, Li X, et al. Penicillium marneffei infection: an emerging disease in mainland China. Mycopathologia. 2013;175(1–2):57–67. doi:10.1007/s11046-012-9577-0
   PubMed Web of Science ®Google Scholar
• Ying RS, Le T, Cai WP, et al. Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011–2017. HIV Med. 2020;21(11):729–738. doi:10.1111/hiv.13024
   PubMed Web of Science ®Google Scholar
• Shu F, Pruksaphon K, Nosanchuk JD, et al. Evaluation of the yeast phase-specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin sandwich ELISA to detect Talaromyces marneffei antigen in human urine. Front Cell Infect Microbiol. 2023;13:1163868. doi:10.3389/fcimb.2023.1163868
   PubMed Web of Science ®Google Scholar
• Chen X, Ou X, Wang H, et al. Talaromyces marneffei Mp1p antigen detection may play an important role in the early diagnosis of Talaromycosis in patients with acquired immunodeficiency syndrome. Mycopathologia. 2022;187(2–3):205–215. doi:10.1007/s11046-022-00618-9
   PubMed Web of Science ®Google Scholar
• Pruksaphon K, Intaramat A, Simsiriwong P, et al. An inexpensive point-of-care immunochromatographic test for Talaromyces marneffei infection based on the yeast phase specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin. PLoS Negl Trop Dis. 2021;15(5):e0009058. doi:10.1371/journal.pntd.0009058
   PubMed Web of Science ®Google Scholar
• Thu NTM, Chan JFW, Ly VT, et al. Superiority of a novel Mp1p antigen detection enzyme immunoassay compared to standard BACTEC blood culture in the diagnosis of Talaromycosis. Clin Infect Dis. 2021;73(2):e330–e336. doi:10.1093/cid/ciaa826
   PubMed Web of Science ®Google Scholar
• Naidoo K, Rampersad S, Karim SA. Improving survival with tuberculosis & HIV treatment integration: a mini-review. Indian J Med Res. 2019;150(2):131–138. doi:10.4103/ijmr.IJMR_660_19
   PubMed Web of Science ®Google Scholar
• Pruksaphon K, Intaramat A, Ratanabanangkoon K, et al. Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing. Diagn Microbiol Infect Dis. 2020;96(3):114959. doi:10.1016/j.diagmicrobio.2019.114959
   PubMed Web of Science ®Google Scholar
• Shen Q, Sheng L, Zhang J, et al. Analysis of clinical characteristics and prognosis of talaromycosis (with or without human immunodeficiency virus) from a non-endemic area: a retrospective study. Infection. 2022;50(1):169–178. doi:10.1007/s15010-021-01679-6
   PubMed Web of Science ®Google Scholar
• Klus J, Ly VT, Chan C, et al. Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort. Med Mycol. 2021;59(4):392–399. doi:10.1093/mmy/myab005
   PubMed Web of Science ®Google Scholar
• Sun J, Sun W, Tang Y, et al. Clinical characteristics and risk factors for poor prognosis among HIV patients with Talaromyces marneffei bloodstream infection. BMC Infect Dis. 2021;21(1):514. doi:10.1186/s12879-021-06232-2
   PubMed Web of Science ®Google Scholar
• Tragiannidis A, Gkampeta A, Vousvouki M, et al. Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opin Drug Saf. 2021;20(9):1061–1074. doi:10.1080/14740338.2021.1922667
   PubMed Web of Science ®Google Scholar
• Romo FT, Aziz M, Livak B, et al. Renal function recovery and HIV viral suppression following Tenofovir discontinuation for renal impairment. J AIDS Clin Res. 2014;5(11). doi:10.4172/2155-6113.1000379
   PubMedGoogle Scholar
• Wei HY, Liang WJ, Li B, et al. Clinical characteristics and risk factors of Talaromyces marneffei infection in human immunodeficiency virus-negative patients: a retrospective observational study. World J Emerg Med. 2021;12(4):281–286. doi:10.5847/wjem.j.1920-8642.2021.04.005
   PubMed Web of Science ®Google Scholar
• Shi M, Lin J, Wei W, et al. Machine learning-based in-hospital mortality prediction of HIV/AIDS patients with Talaromyces marneffei infection in Guangxi, China. PLoS Negl Trop Dis. 2022;16(5):e0010388. doi:10.1371/journal.pntd.0010388
   PubMed Web of Science ®Google Scholar
• Nascimento L, Improta-Caria AC, Brites C. Mortality in hospitalized HIV-infected patients in a referral center in Bahia, Brazil. Braz J Infect Dis. 2022;26(6):102716. doi:10.1016/j.bjid.2022.102716
   PubMed Web of Science ®Google Scholar
• Pacholec M, Sami F, Newell K, et al. Fatal disseminated Mycobacterium haemophilum infection involving the central nervous system in a renal transplant recipient. J Clin Tuberc Other Mycobact Dis. 2020;21:100197. doi:10.1016/j.jctube.2020.100197
   PubMedGoogle Scholar
• Sandler BJ, Davis KA, Schuster KM. Symptomatic human immunodeficiency virus-infected patients have poorer outcomes following emergency general surgery: a study of the nationwide inpatient sample. J Trauma Acute Care Surg. 2019;86(3):479–488. doi:10.1097/TA.0000000000002161
   PubMed Web of Science ®Google Scholar
• Xiao J, Du S, Tian Y, et al. Causes of death among patients infected with HIV at a tertiary care hospital in China: an observational cohort study. AIDS Res Hum Retroviruses. 2016;32(8):782–790. doi:10.1089/aid.2015.0271
   PubMed Web of Science ®Google Scholar
• Wu J, Lu AD, Zhang LP, et al. Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2019;40(1):52–57.
   PubMedGoogle Scholar
• Zheng J, Gui X, Cao Q, et al. A clinical study of acquired immunodeficiency syndrome associated Penicillium marneffei infection from a non-endemic area in China. PLoS One. 2015;10(6):e0130376. doi:10.1371/journal.pone.0130376
   PubMed Web of Science ®Google Scholar
• Qin Y, Zhou Y, Liu S, et al. HIV-associated talaromycosis: does timing of antiretroviral therapy matter? J Infect. 2022;84(3):410–417. doi:10.1016/j.jinf.2021.12.032
   PubMed Web of Science ®Google Scholar
• Pang CG, Yang XG, Zhao YL, et al. A novel tool for predicting the survival of endoprosthesis used for reconstruction of the knee following tumor resection: a retrospective cohort study. BMC Cancer. 2021;21(1):986. doi:10.1186/s12885-021-08710-x
   PubMed Web of Science ®Google Scholar